An urgent call to action to treat combined epidemics
Glucose tolerance is an independent predictor of overall mortality and hepatic decompensation in patients with HCV cirrhosis.
Ledipasvir/sofosbuvir is safe and effective for hepatitis C virus patients who fail on simeprevir/ sofosbuvir.
Real-world study shows efficacy of sofosbuvir/velpatasvir for 12 weeks
Sofosbuvir-velpatasvir-voxilaprevir provides salvage therapy for NS5A failures
Despite the availability of new, highly successful direct-acting antiviral (DAA) regimens, more than one third of chronic hepatitis C (HCV) patients are denied access to treatment by their insurance provider, according to a new study.
Treatment with a combination of ledipasvir and sofosbuvir can lead to large economic gains.
Clinicians need to carefully plan treatment when prescribing DAA therapy for patients infected with hepatitis C virus who have hepatocellular carcinoma.
All hepatitis C virus genotypes respond to therapy
Recipients of hepatitis C-infected kidneys treated with direct-acting antiviral agents are disease-free one year post-transplant.